Document:

Exhibit 4.15

 

AMENDMENT 2 TO SENIOR SECURED PROMISSORY
NOTE 

 

This AMENDMENT 2, dated
November 21, 2017 (the “Amendment”), to that certain senior secured promissory note of ADial Pharmaceuticals,
LLC, as predecessor-in-interest to Adial Pharmaceuticals, Inc. (the “Company”), in the original principal amount
of $287,500.00, dated May 1, 2017, as amended, (the “Note”) held by FirstFire Global Opportunities Fund LLC
(“Holder”) is entered into by and between the Company and Holder. Capitalized terms used herein and not defined
shall have the meanings set forth in the Note.

 

WITNESSETH:

 

WHEREAS,
the Maturity Date of the Note is December 4, 2017;

 

WHEREAS,
the Company and Holder desire to extend the Maturity Date to February 5, 2018 upon the terms and conditions set forth herein;

 

 NOW, THEREFORE,
in consideration of the premises, and for other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the parties hereto agree to amend the Note as follows:

 

		1.	The Maturity Date shall mean, and be extended to, February 5, 2018.

		2.	On the Maturity Date the Company shall pay to Holder, and the Holder will accept, the sum of $375,000 in full and complete
satisfaction of the principal sum of the Note and all accrued and unpaid interest thereon.

		3.	The Note, as amended by this Amendment, contains the entire agreement between the parties hereto
regarding the subject matter thereof, and there are no agreements, warranties or representations which are not set forth therein
or herein. This Amendment may not be modified or amended except by an instrument in writing duly signed by or on behalf of the
parties hereto.

		4.	This Amendment shall be governed by and construed and enforced in accordance with the local laws
of the State of New York applicable to agreements made and to be performed entirely within the State, without regard to conflict
of laws principles.

		5.	This Amendment may be executed simultaneously in any number of counterparts, each of which shall
be deemed an original but all of which together shall constitute one and the same instrument.

 

	Adial Pharmaceuticals, Inc. 

         

         

         

         

        By:   /s/ William Stilley                                  

        Name: William Stilley

        Title: Chief Executive Officer

 

 	FirstFire Global Opportunities Fund LLC

         

        By FirstFire Capital Management LLC, its manager

         

         

        By:   /s/ Eli Fireman                                                   

        Name: Eli FiremanExhibit
4.16

 

THE
ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE
OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR (B) AN OPINION OF COUNSEL (WHICH MAY BE THE LEGAL COUNSEL OPINION (AS DEFINED IN THE PURCHASE AGREEMENT)), IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	Principal
    Amount: $[     ].00	Issue
    Date: November 21, 2017
	Actual
    Amount of Purchase Price: $[  ],000.00	 

 

FORM
OF SENIOR SECURED PROMISSORY NOTE

 

FOR
VALUE RECEIVED, ADIAL PHARMACEUTICALS, INC., a Delaware corporation (hereinafter called the “Borrower”
or the “Company”), hereby promises to pay to the order of [              ], or his registered assigns (the “Holder”),
in the form of lawful money of the United States of America, the principal sum of $[              ].00, which amount is the $[              ],000.00 actual
amount of the purchase price (the “Consideration”) hereof plus a prorated 15% original issue discount (the “OID”)
(subject to adjustment pursuant to Section 3) (the “Principal Amount”) and to pay interest on the unpaid Principal
Amount hereof at the rate of two percent (2%) (the “Interest Rate”) per annum from the date hereof (the “Issue
Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment or otherwise, as
further provided herein. The maturity date shall be six (6) months from the Issue Date (the “Maturity Date”), and
is the date upon which the principal sum, the applicable portion of the OID, as well as any accrued and unpaid interest and other
fees herein, shall be due and payable.

 

This
Note may be prepaid or repaid in whole or in part at any time as provided herein. Subject to Section 2.1 below, this Note shall
be a senior secured obligation of the Company, with priority over all future Indebtedness (as defined below) of the Company as
provided for herein. The obligations of the Company under this Note are secured pursuant to the terms of the security agreement
of even date (the “Security Agreement) by and among the Borrower, its Subsidiaries, and the Secured Parties (as defined
therein), and such security interest includes but is not limited to all of the assets of the Company and its Subsidiaries.

 

Interest
shall commence accruing on the date that the Note is fully funded and shall be computed on the basis of a 365-day year and the
actual number of days elapsed. Any Principal Amount or interest on this Note which is not paid when due shall bear interest at
the rate of fifteen percent (15%) per annum from the due date thereof until the same is paid (“Default Interest”).

 

All
payments due hereunder shall be made in lawful money of the United States of America. All payments shall be made at such address
as the Holder shall hereafter give to the Borrower by written notice made in accordance with the provisions of this Note. Whenever
any amount expressed to be due by the terms of this Note is due on any day which is not a business day, the same shall instead
be due on the next succeeding day which is a business day and, in the case of any interest payment date which is not the date
on which this Note is paid in full, the extension of the due date thereof shall not be taken into account for purposes of determining
the amount of interest due on such date.

 

Each
capitalized term used herein, and not otherwise defined, shall have the meaning ascribed thereto in that certain Securities Purchase
Agreement dated as of the Issue Date (the “Purchase Agreement”), pursuant to which this Note was originally issued.
As used in this Note, the term “business day” shall mean any day other than a Saturday, Sunday or a day on which commercial
banks in the city of New York, New York are authorized or required by law or executive order to remain closed. As used herein,
the term “Trading Day” means any day that shares of Common Stock are listed for trading or quotation on the OTCBB
(as defined in the Purchase Agreement), any tier of the NASDAQ Stock Market, the New York Stock Exchange or the NYSE American
LLC.

 

This
Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive
rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

 

    	 	1	 

     

    

 

The
following terms shall apply to this Note:

 

ARTICLE
I. REPAYMENT RIGHTS

 

1.1
Effect of Certain Events.

 

(a)
Effect of Merger, Consolidation, Etc. At the option of the Holder, the sale, conveyance or disposition of all or substantially
all of the assets of the Borrower, or the consolidation, merger or other business combination (other than a reincorporation merger
or a reorganization to convert to a corporation) of the Borrower with or into any other Person (as defined below) or Persons when
the Borrower is not the survivor or where the majority owners of Borrower prior to the transaction are not the majority owners
of the surviving entity shall be deemed to be an Event of Default (as defined in Article III) pursuant to which the Borrower shall
be required to pay to the Holder upon the consummation of and as a condition to such transaction until this Note is paid in full
an amount equal to the Default Amount (as defined herein). “Person” shall mean any individual, corporation, limited
liability company, partnership, association, trust or other entity or organization. The Borrower shall not effectuate any transaction
described in this Section 1.1(a), including but not limited to a reincorporation merger or a reorganization to convert to a corporation,
unless (a) it first gives, to the extent practicable, at least thirty (30) days prior written notice (but in any event at least
fifteen (15) days prior written notice of the record date of the special meeting of shareholders to approve, or if there is no
such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization, reorganization or other
similar event or sale of assets, and (b) the resulting successor or acquiring entity (if not the Borrower) assumes by written
instrument the obligations of this Note. The above provisions shall similarly apply to successive consolidations, mergers, sales,
transfers or share exchanges.

 

(b)
Adjustment Due to Distribution. If the Borrower shall declare or make any distribution of its assets (or rights to acquire
its assets) to holders of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any
dividend or distribution to the Borrower’s shareholders in cash or shares (or rights to acquire shares) of capital stock
of a subsidiary (i.e., a spin-off)) (a “Distribution”), then the Borrower shall be required to pay to the Holder the
Default Amount within one (1) business day.

 

(c)
If the Company enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase Agreement, then the
Borrower shall be required to pay to the Holder the Default Amount within one (1) business day.

 

1.3
Prepayment. Notwithstanding anything to the contrary contained in this Note, at any time or prior to (but not following)
the earlier of the (i) the close of business three (3) days after the date that an Event of Default occurs hereunder and (ii)
Maturity Date, the Borrower shall have the right to prepay the outstanding Principal Amount and interest (including any Default
Interest) then due under this Note, in whole or in part, in accordance with this Section 1.3. Any prepayment must be delivered
with notice and such notice of prepayment hereunder (an “Optional Prepayment Notice”) shall be delivered to the Holder
of the Note at its registered addresses and shall state: (1) that the Borrower is exercising its right to prepay the Note, and
(2) the date of prepayment which shall be not more than three (3) business days after the date of the Optional Prepayment Notice.
On the date fixed for prepayment (the “Optional Prepayment Date”), the Borrower shall make payment of an amount in
cash equal to the sum of: (w) the lesser of: (i) 108.65% and (ii) the maximum allowed by law multiplied by the Principal Amount
then outstanding plus (x) accrued and unpaid interest on the Principal Amount to the Optional Prepayment Date plus
(y) Default Interest, if any, on the amounts referred to in clauses (w) and (x).

 

1.4
Repayment from Proceeds. While any portion of the outstanding Principal Amount and interest (including Default Interest)
under this Note are due and owing, if the Company receives net cash proceeds from any source or series of related or unrelated
sources, including but not limited to, from the issuance of equity or debt, the conversion of outstanding warrants of the Borrower,
the issuance of securities pursuant to an equity line of credit of the Borrower or the sale of assets, in the aggregate amount
of more than $250,000.00, the Borrower shall, within three (3) business days of Borrower’s receipt of such proceeds, inform
the Holder of such receipt, following which the Holder shall have the right in its sole discretion to require the Borrower to
immediately apply all or any portion of such proceeds to repay all or any portion of the outstanding Principal Amount and interest
(including any Default Interest) then due under this Note. Failure of the Borrower to comply with this provision shall constitute
an Event of Default. In the event that such proceeds are received by the Holder prior to the Maturity Date, the required prepayment
shall be subject to the terms of Section 1.3 herein.

 

    	 	2	 

     

    

 

ARTICLE
II. RANKING AND CERTAIN COVENANTS

 

2.1
Ranking and Security. The obligations of the Borrower under this Note shall rank senior with respect to any and all Indebtedness
incurred as of or following the Issue Date. The obligations of the Borrower under this Note are secured pursuant to that certain
Security Agreement of even date. The obligations of the Company under this Note are secured pursuant to the terms of the Security
Agreement by and among the Borrower, its Subsidiaries, and the Secured Parties, and such security interest includes but is not
limited to all of the assets of the Company and its Subsidiaries. Notwithstanding the foregoing, the obligations of the Borrower
under this Note shall rank junior to any Indebtedness issued to FirstFire Global Opportunities Fund LLC on or prior to the date
hereof.

 

2.2
Other Indebtedness. So long as the Borrower shall have any obligation under this Note, the Borrower shall not (directly
or indirectly through any Subsidiary or affiliate) incur or suffer to exist or guarantee any Indebtedness that is senior to or
pari passu with (in priority of payment and performance) the Borrower’s obligations hereunder. As used in this Section 2.2,
the term “Borrower” means the Borrower and any Subsidiary of the Borrower. As used herein, the term “Indebtedness”
means (a) all indebtedness of the Borrower for borrowed money or for the deferred purchase price of property or services, including
any type of letters of credit, but not including deferred purchase price obligations in place as of the Issue Date or obligations
to trade creditors incurred in the ordinary course of business, (b) all obligations of the Borrower evidenced by notes, bonds,
debentures or other similar instruments, (c) all guarantee obligations of the Borrower in respect of obligations of the kind referred
to in clauses (a) through (b) above that the Borrower would not be permitted to incur or enter into, and (d) all obligations of
the kind referred to in clauses (a) through cd) above that the Borrower is not permitted to incur or enter into that are secured
and/or unsecured by (or for which the holder of such obligation has an existing right, contingent or otherwise, to be secured
and/or unsecured by) any lien or encumbrance on property (including accounts and contract rights) owned by the Borrower, whether
or not the Borrower has assumed or become liable for the payment of such obligation.

 

2.3
Distributions on Capital Stock. So long as the Borrower shall have any obligation under this Note, the Borrower shall not
without the Holder’s written consent (a) pay, declare or set apart for such payment, any dividend or other distribution
(whether in cash, property or other securities) on shares of capital stock other than dividends on shares of Common Stock solely
in the form of additional shares of Common Stock or (b) directly or indirectly or through any subsidiary make any other payment
or distribution in respect of its capital stock except for distributions pursuant to any shareholders’ rights plan which
is approved by a majority of the Borrower’s disinterested directors.

 

2.4
Restriction on Stock Repurchases and Debt Repayments. So long as the Borrower shall have any obligation under this Note,
the Borrower shall not without the Holder’s written consent redeem, repurchase or otherwise acquire (whether for cash or
in exchange for property or other securities or otherwise) in any one transaction or series of related transactions any shares
of capital stock of the Borrower or any warrants, rights or options to purchase or acquire any such shares, or repay any pari
passu or subordinated indebtedness of Borrower.

 

2.5
Sale of Assets. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the
Holder’s written consent, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary
course of business. Any consent to the disposition of any assets may be conditioned on a specified use of the proceeds of disposition.

 

2.6
Advances and Loans; Affiliate Transactions. So long as the Borrower shall have any obligation under this Note, the Borrower
shall not, without the Holder’s written consent, lend money, give credit, make advances to or enter into any transaction
with any person, firm, joint venture or corporation, including, without limitation, officers, directors, employees, subsidiaries
and affiliates of the Borrower, except loans, credits or advances (a) in existence or committed on the Issue Date and which the
Borrower has informed Holder in writing prior to the Issue Date, (b) in regard to transactions with unaffiliated third parties,
made in the ordinary course of business or (c) in regard to transactions with unaffiliated third parties, not in excess of $50,000.
So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder’s written
consent, repay any affiliate (as defined in Rule 144) of the Borrower in connection with any indebtedness or accrued amounts owed
to any such party.

 

    	 	3	 

     

    

 

2.7
Preservation of Business and Existence, etc. So long as the Borrower shall have any obligation under this Note, the Borrower
shall not, without the Holder’s written consent, change the nature of its business. In addition, so long as the Borrower
shall have any obligation under this Note, the Borrower shall maintain and preserve, and cause each of its Subsidiaries to maintain
and preserve, its existence, rights and privileges, and become or remain, and cause each of its Subsidiaries (other than dormant
Subsidiaries that have no or minimum assets) to become or remain, duly qualified and in good standing in each jurisdiction in
which the character of the properties owned or leased by it or in which the transaction of its business makes such qualification
necessary. Furthermore, so long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the
Holder’s written consent, solicit any offers for, respond to any unsolicited offers for, or conduct any negotiations with,
any other person or entity with respect to any Variable Rate Transaction or investment.

 

2.8
Noncircumvention. The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate or
Articles of Organization or Operating Agreement, or through any reorganization, transfer of assets, consolidation, merger, scheme
of arrangement, dissolution, issue or sale of securities (other than a reincorporation merger or reorganization to convert to
a corporation), or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Note, and will at all times in good faith carry out all the provisions of this Note and take all action as may be required to
protect the rights of the Holder.

 

2.9
Lost, Stolen or Mutilated Note. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of this Note, and, in the case of loss, theft or destruction, of any indemnification undertaking
by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Note, the
Company shall execute and deliver to the Holder a new Note.

 

ARTICLE
III. EVENTS OF DEFAULT

 

It
shall be considered an event of default if any of the following events listed in this Article III (each, an “Event of Default”)
shall occur; provided, however, that, except in the case of the Events of Default listed in Sections 3.1, 3.2, 3.7, 3.9,
3.10, 3.16, 3.18, 3.19 or 3.20 below, the Borrower shall have five (5) business days to cure such Event of Default unless a lesser
number of days is required pursuant to the provisions of this Article III:

 

3.1
Failure to Pay Principal or Interest. The Borrower fails to pay the Principal Amount hereof or interest thereon when due
on this Note, whether at maturity, upon acceleration or otherwise, and has failed to cure such default within three (3) days of
notice thereof.

 

3.2
This section intentionally left blank.

 

3.3
Breach of Agreements and Covenants. The Borrower breaches any material agreement, covenant or other material term or condition
contained in the Purchase Agreement, this Note, the Warrant described in the Purchase Agreement, the Irrevocable Transfer Agent
Instructions or in any agreement, statement or certificate given in writing pursuant hereto or in connection herewith or therewith.

 

3.4
Breach of Representations and Warranties. Any material representation or warranty of the Borrower made in the Purchase
Agreement, this Note, the Warrant described in the Purchase Agreement, the Irrevocable Transfer Agent Instructions or in any agreement,
statement or certificate given in writing pursuant hereto or in connection herewith or therewith shall be false or misleading
in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect
on the rights of the Holder with respect to this Note or the Purchase Agreement.

 

3.5
Receiver or Trustee. The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors,
or apply for or consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business,
or such a receiver or trustee shall otherwise be appointed.

 

3.6
Judgments. Any money judgment, writ or similar process shall be entered or filed against the Borrower or any subsidiary
of the Borrower or any of its property or other assets for more than $50,000, and shall remain unvacated, unbonded or unstayed
for a period of sixty (60) days unless otherwise consented to by the Holder, which consent will not be unreasonably withheld.

 

3.7
Bankruptcy. Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary,
for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any
subsidiary of the Borrower.

 

    	 	4	 

     

    

 

3.8
Delisting of Common Stock. If at any time after the listing of the Common Stock on at least one of the Over the Counter
Bulletin Board, the OTCQB Market, any level of the OTC Markets, or any level of the Nasdaq Stock Market or the New York Stock
Exchange (including the NYSE MKT), the Borrower shall fail to maintain the listing of the Common Stock on at least one of the
Over the Counter Bulletin Board, the OTCQB Market, any level of the OTC Markets, or any level of the Nasdaq Stock Market or the
New York Stock Exchange (including the NYSE MKT).

 

3.9 Failure
to Comply with the 1934 Act. If at any time after the Borrower becomes subject to the reporting requirements of the 1934
Act, the Borrower shall fail to comply with the reporting requirements of the 1934 Act and/or the Borrower shall cease to be
subject to the reporting requirements of the 1934 Act, including but not limited to the Borrower’s filing of any
Notification of Late Filing on Form 12b-25 with the SEC.

 

3.10
Liquidation. Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

 

3.11
Cessation of Operations. Any cessation of operations by Borrower or Borrower admits it is otherwise generally unable to
pay its debts as such debts become due, provided, however, that any disclosure of the Borrower’s ability to continue as
a “going concern” shall not be an admission that the Borrower cannot pay its debts as they become due.

 

3.12
Maintenance of Assets. The failure by Borrower to maintain any material intellectual property rights, personal, real property
or other assets which are necessary to conduct its business (whether now or in the future).

 

3.14 Reverse
Splits. The Borrower effectuates a reverse split of its Common Stock without twenty (20) days prior written notice to the
Holder.

 

3.15
Replacement of Transfer Agent. In the event that terms for conversion are incorporated into this Note, pursuant to Section
1.1(e) of this Note, and the Borrower fails to provide, prior to the effective date of the replacement of its transfer agent,
a fully executed irrevocable transfer agent instructions (including but not limited to the provision to irrevocably reserve shares
of Common Stock in the Reserved Amount) signed by the successor transfer agent to Borrower and the Borrower.

 

3.16
DTC “Chill”. The DTC places a “chill” (i.e. a restriction placed by DTC on one or more of DTC’s
services, such as limiting a DTC participant’s ability to make a deposit or withdrawal of the security at DTC) on any of
the Borrower’s securities.

 

3.17 Illegality.
Any court of competent jurisdiction issues an order declaring this Note, the Purchase Agreement or any provision hereunder or
thereunder to be illegal.

 

3.18.
DWAC Eligibility. In addition to the Event of Default in Section 3.16, if at any time after the listing of the Common Stock
on at least one of the Over the Counter Bulletin Board, the OTCQB Market, any level of the OTC Markets, or any level of the Nasdaq
Stock Market or the New York Stock Exchange (including the NYSE MKT), the Common Stock is otherwise not eligible for trading through
the DTC’s Fast Automated Securities Transfer or Deposit/Withdrawal at Custodian programs.

 

3.19
Cross-Default. The declaration of an event of default by any lender or other extender of credit to the Company under any
notes, loans, agreements or other instruments of the Company evidencing any Indebtedness of the Company (including those filed
as exhibits to or described in the Company’s filings with the SEC), after the passage of all applicable notice and cure
or grace periods.

 

3.20
Variable Rate Transactions. The Borrower (i) issues shares of Common Stock (or convertible securities) pursuant to an equity
line of credit of the Company or otherwise in connection with a Variable Rate Transaction (whether now existing or entered into
in the future) or (ii) adjusts downward the “floor price” at which shares of Common Stock (or convertible securities)
may be issued under an equity line of credit or otherwise in connection with a Variable Rate Transaction (whether now existing
or entered into in the future).

 

    	 	5	 

     

    

 

3.21
Rights and Remedies Upon an Event of Default. Subject to applicable cure periods specifically provided for herein, upon
the occurrence and during the continuation of any Event of Default specified in this Article III, exercisable through the delivery
of written notice to the Borrower by the Holder (the “Default Notice”) (provided, however, that no Default Notice
need be provided by the Holder and no notice and no cure period shall apply in the case of the Events of Default specified in
Sections 3.1, 3.2, 3.7, 3.9, 3.10, 3.16, 3.18, 3.19 or 3.20 above), this Note shall become immediately due and payable and the
Borrower shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount (the “Default Amount”)
equal to the Principal Amount then outstanding plus accrued interest (including any Default Interest) through the date of full
repayment plus an additional $25,000.00 per each calendar month that the Note has been in default until payment in full. Upon
an uncured Event of Default, all amounts payable hereunder shall immediately become due and payable, all without demand, presentment
or notice, all of which hereby are expressly waived by the Borrower, together with all costs, including, without limitation, legal
fees and expenses, of collection, and the Holder shall be entitled to exercise all other rights and remedies available at law
or in equity, including, without limitation, those set forth in Section 3.22 below.

 

3.22
Holder’s Right to Confession of Judgment. Upon the occurrence and during the continuation of any Event of Default,
and in addition to any other right or remedy of the Holder hereunder, under the Purchase Agreement or otherwise at law or in equity,
the Borrower hereby irrevocably authorizes and empowers Holder or its legal counsel, each as the Borrower’s attorney-in-fact,
to appear ex parte and without notice to the Borrower to confess judgment against the Borrower for the unpaid amount of this Note
as evidenced by the Affidavit of Confession of Judgment signed by the Borrower as of the Issue Date and to be completed by the
Holder or its counsel pursuant to the foregoing power of attorney (which power is coupled with an interest), a copy of which is
attached as Exhibit A hereto (the “Affidavit”). The Affidavit shall set forth the amount then due hereunder, plus
attorney’s fees and cost of suit, and to release all errors, and waive all rights of appeal. The Borrower waives the right
to contest Holder’s rights under this Section 3.22, including without limitation the right to any stay of execution and
the benefit of all exemption laws now or hereafter in effect. No single exercise of the foregoing right and power to confess judgment
will be deemed to exhaust such power, whether or not any such exercise shall be held by any court to be invalid, voidable, or
void, and such power shall continue undiminished and may be exercised from time to time as the Holder may elect until all amounts
owing on this Note have been paid in full.

 

3.23
Failure to Issue. If the Borrower fails to issue the Commitment Shares (as defined in the Purchase Agreement), Warrant
(as defined in the Purchase Agreement), or Warrant Shares (as defined in the Purchase Agreement) within the required timeframe
as provided therein.

 

ARTICLE
IV. MISCELLANEOUS

 

4.1
Failure or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or
privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege
preclude other or further exercise thereof or of any other right, power or privileges. All rights and remedies of the Holder existing
hereunder are cumulative to, and not exclusive of, any rights or remedies otherwise available.

 

4.2
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, e-mail or facsimile, addressed as set forth below or to such other address as
such party shall have specified most recently by written notice. Any notice or other communication required or permitted to be
given hereunder shall be deemed effective (a) upon hand delivery or delivery by e-mail or facsimile, with accurate confirmation
generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during
normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other
than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following
the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing,
whichever shall first occur. The addresses for such communications shall be:

 

If
to the Borrower, to:

 

ADIAL
PHARMACEUTICALS, INC.

1180
Seminole Trail, Suite 495Charlottesville, VA 22901

Attention:
William Stilley

e-mail:
wstilley@adialpharma.com

 

    	 	6	 

     

    

 

With
a copy by e-mail only to (which copy shall not constitute notice):

 

GRACIN
& MARLOW, LLP

405
Lexington Avenue

26th
Floor

New
York, New York 10174

Attn:
Leslie Marlow, Esq.

e-mail:
lmarlow@gracinmarlow.com

 

If
to the Holder:

 

Addressed
to the Holder at the relevant address stated in the Purchase Agreement or to such other address or telecopy number as the party
to whom notice is to be given may have furnished to the other party in writing in accordance herewith.

 

4.3
Amendments. This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and
the Holder. The term “Note” and all reference thereto, as used throughout this instrument, shall mean this instrument
as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

4.4
Assignability. This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit
of the Holder and its successors and assigns. Each transferee of this Note must be an “Accredited Investor” (as defined
in the Purchase Agreement).

 

4.5 Cost
of Collection. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of
collection, including reasonable attorneys’ fees.

 

4.6
Governing Law; Venue; Attorney’s Fees. This Note shall be governed by and construed in accordance
with the laws of the State of New York without regard to principles of conflicts of laws. Any action brought by either party against
the other concerning the transactions contemplated by this Note or any other agreement, certificate, instrument or document contemplated
hereby shall be brought only in the state courts of New York or in the federal courts located in the state and county of New York.
The Borrower hereby irrevocably waives any objection to jurisdiction and venue of any action instituted hereunder and shall not
assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. THE BORROWER HEREBY IRREVOCABLY
WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
WITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTIONS CONTEMPLATED HEREBY. Each party hereby irrevocably waives personal
service of process and consents to process being served in any suit, action or proceeding in connection with this Note or
any other agreement, certificate, instrument or document contemplated hereby or thereby by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under
this Note and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. The prevailing party
in any action or dispute brought in connection with this the Note or any other agreement, certificate, instrument or document
contemplated hereby or thereby shall be entitled to recover from the other party its reasonable attorney’s fees and costs.

 

4.7
Certain Amounts. Whenever pursuant to this Note the Borrower is required to pay an amount in excess of the outstanding
Principal Amount (or the portion thereof required to be paid at that time) plus accrued and unpaid interest plus Default Interest
on such interest, the Borrower and the Holder agree that the actual damages to the Holder from the receipt of cash payment on
this Note may be difficult to determine and the amount to be so paid by the Borrower represents stipulated damages and not a penalty
and is intended to compensate the Holder in part for its loss. The Borrower and the Holder hereby agree that such amount of stipulated
damages is not plainly disproportionate to the possible loss to the Holder.

 

    	 	7	 

     

    

 

4.8
Purchase Agreement. The Company and the Holder shall be bound by the applicable terms of the Purchase Agreement and the
documents entered into in connection herewith and therewith.

 

4.9
This section intentionally left blank.

 

4.10
Remedies. The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Holder, by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that
the remedy at law for a breach of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened
breach by the Borrower of the provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies
at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this Note and to enforce specifically the terms and provisions thereof, without the necessity of showing
economic loss and without any bond or other security being required.

 

4.11
Construction; Headings. This Note shall be deemed to be jointly drafted by the Company and all the Holder and shall not
be construed against any person as the drafter hereof. The headings of this Note are for convenience of reference and shall not
form part of, or affect the interpretation of, this Note.

 

4.12
Usury. To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever
claim, and will resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now
or at any time hereafter in force, in connection with any action or proceeding that may be brought by the Holder in order to enforce
any right or remedy under this Note. Notwithstanding any provision to the contrary contained in this Note, it is expressly agreed
and provided that the total liability of the Company under this Note for payments which under New York law are in the nature of
interest shall not exceed the maximum lawful rate authorized under applicable law (the “Maximum Rate”), and, without
limiting the foregoing, in no event shall any rate of interest or default interest, or both of them, when aggregated with any
other sums which under New York law in the nature of interest that the Company may be obligated to pay under this Note exceed
such Maximum Rate. It is agreed that if the maximum contract rate of interest allowed by New York law and applicable to this Note
is increased or decreased by statute or any official governmental action subsequent to the Issue Date, the new maximum contract
rate of interest allowed by law will be the Maximum Rate applicable to this Note from the effective date thereof forward, unless
such application is precluded by applicable law. If under any circumstances whatsoever, interest in excess of the Maximum Rate
is paid by the Company to the Holder with respect to indebtedness evidenced by this the Note, such excess shall be applied by
the Holder to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of handling such
excess to be at the Holder’s election.

 

4.13
Severability. In the event that any provision of this Note is invalid or unenforceable under any applicable statute or
rule of law (including any judicial ruling), then such provision shall be deemed inoperative to the extent that it may conflict
therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may prove invalid
or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Note.

 

4.14
Most Favored Nation. While the Note or any principal amount, interest or fees or expenses due thereunder remain outstanding
and unpaid, the Company shall not enter into any public or private offering of its securities (including securities convertible
into shares of Common Stock) with any individual or entity (an “Other Investor”) that has the effect of establishing
rights or otherwise benefiting such Other Investor in a manner more favorable in any material respect to such Other Investor than
the rights and benefits established in favor of the Buyer by this Agreement or the Note unless, in any such case, the Buyer has
been provided with written notice (the “Company Notice”) and no less than 10 days to exercise the right, but not the
obligation, to exchange its rights and obligations hereunder (i.e. to the Securities) for the rights and obligations established
with the Other Investor, except that Buyer shall retain a senior position to the Other Investor . In order to exercise such right,
Buyer shall send the Company a written notice of its exercise (the “Buyer Notice”). If the Buyer Notice is not received
by the Company within ten (10) days of Buyer’s receipt of the Company Notice, the rights under this Section 4.14 shall terminate
only with respect to such offering of the Company’s securities as identified in the respective Company Notice, and not with
respect to any future public or private offering by the Company of its securities (including securities convertible into shares
of Common Stock).

 

4.15
Notwithstanding anything to the contrary contained herein, the reincorporation of Borrower in another state or the conversion
of Borrower into a corporation or any other similar transaction intended to effectuate the change to an entity appropriate for
an initial public offering shall have not trigger an adjustment or other action under this Note and shall not be an Event of Default,
provided, however, that the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument or operation
by law the obligations of this Note.

 

[signature
page follows]

 

    	 	8	 

     

    

 

IN
WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer on November 21, 2017.

 

	ADIAL PHARMACEUTICALS, INC.	 
	 	 	 
	By:	           	 
		Name: William
    Stilley	 
		Title: Chief Executive Officer	 

 

    	 	9	 

     

    

 

EXHIBIT
A

 

Affidavit
of Confession of Judgment

 

	SUPREME COURT OF THE STATE OF NEW YORK 	 	 
	COUNTY OF NEW YORK	 	 
	 	 	 
	----------------------------------------------------------------------- ☒	 	 
	[ ],	 	 
	 	 	Index No.
	Plaintiff,	 	 
	- against -	 	AFFIDAVIT OF 

CONFESSION OF 

JUDGMENT
	 	 	 
	ADIAL PHARMACEUTICALS, INC.,	 	 
	 	 	 
	Defendant.	 	 
	 	 	 
	----------------------------------------------------------------------- ☒	 	 
	 	 	 
	STATE OF NEW YORK                 )	 	 
	                                                       )         ss.: 	 	 
	COUNTY OF NEW YORK        )	 	 

 

William
Stilley, being duly sworn, hereby deposes and says:

 

1.
I am the Chief Executive Officer of defendant ADIAL PHARMACEUTICALS, INC. (“Borrower”). As such, I am fully familiar
with all the facts and circumstances recited herein on personal knowledge. Borrower has its principal place of business at 1180
Seminole Trail, Suite 495, Charlottesville, VA 22901. On behalf of the Borrower, I hereby confess judgment in favor of [ ] (“Holder”),
residing at [ ], in the amount of the Default Amount (as defined in the senior secured promissory note between of the parties,
dated November 21, 2017 (the “Note”)), less any payments made on or after the date of this affidavit of confession
of judgment, plus interest a default interest rate of fifteen percent (15%) percent per annum on said amount. In no event shall
interest payable hereunder exceed the maximum permissible under applicable law.

 

     

     

    

 

2.
I hereby authorize the Supreme Court of the State of New York to enter judgment against Borrower in the amount of in the
amount of the Default Amount plus a default interest rate of fifteen percent (15%) per annum on said amount from the date of
any default, plus the costs and attorneys’ fees that are set forth below, less any payments made on or after the date
of this affidavit of confession of judgment, upon Borrower’s failure for any reason to timely make any payment to
Lender called for by the Note, due to Borrower’s breach of Section 3.1 of the Note (failure to pay Principal or
Interest) or due to Borrower’s breach of its obligations that it owes to Lender pursuant to Sections 3.2-3.20 of the
Note.

 

3.
In order to secure these obligations, Borrower agreed to simultaneously deliver with the execution of the Note this Affidavit
of Confession of Judgment.

 

4.
The sums confessed pursuant to this affidavit of confession of judgment are justly due and owing to Lender under the following
circumstances: Borrower entered into the Note pursuant to which Borrower promised to pay to the order of Lender the Default Amount
plus interest as provided for therein. The amounts confessed by this affidavit represent a convertible note investment by Lender
in Borrower and arise out of Borrower’s breach of its obligations under the Note.

 

5.
Borrower agrees to pay any and all costs and expenses incurred by Lender in enforcing the terms of this affidavit of confession
of judgment, including reasonable attorneys’ fees and expenses at the rate of $475.00 per hour that Lender incurs or is
billed for in connection with enforcing the terms of the affidavit of confession of judgment, entering any Judgment, collecting
upon said Judgment, and defending or prosecuting any appeals.

 

     

     

    

 

	 	ADIAL PHARMACEUTICALS, INC.
	 	 	 
	 	By:	 
	 	Name:	William Stilley
	 	Title:	Chief Executive Officer

 

     

     

    

 

STATE
OF _________________          )

ss.:

COUNTY
OF _________________ )

 

ACKNOWLEDGMENT

 

On
____________________, 2017 before me personally came                                                                                                    ,
to me known, who, by me duly sworn, did depose and say that deponent
is an officer of ADIAL PHARMACEUTICALS, INC., the corporation described in, and which executed the foregoing affidavit of confession
of judgment, that deponent knows the seal of the corporation, that the seal affixed to the affidavit of confession of judgment
is the corporation’s seal, that it was affixed by order of the board of directors of the corporation and that deponent signed
deponent’s name by like order.

 

 

 

Notary
Public

 

SEAL:

 

[Signature
Page to Affidavit of Confession of Judgment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00277-of-00352.parquet"}]]